» Articles » PMID: 8692287

Effects of Noradrenaline and Neuropeptide Y on Rat Mesenteric Microvessel Contraction

Overview
Specialty Pharmacology
Date 1996 Feb 1
PMID 8692287
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

We have studied the contractile effects of the sympathetic transmitter noradrenaline and its cotransmitter neuropeptide Y (NPY) given alone and in combination on isolated rat mesenteric resistance vessels (200-300 microns diameter). Noradrenaline and NPY each concentration-dependently contracted rat mesenteric microvessels (EC50 approximately equal to 800 nM and 10 nM, respectively), but noradrenaline caused considerably greater maximal effects than NPY (14.3 mN vs. 3.5 mN). A low antagonistic potency of yohimbine indicated that the response to noradrenaline did not involve alpha 2-adrenoceptors, and the subtype-selective antagonists 5-methylurapidil, tamsulosin and chloroethylclonidine indicated mediation via an alpha 1A-adrenoceptor. Shallow Schild regressions for prazosin and 5-methylurapidil indicated that an alpha 1-adrenoceptor subtype with relatively low prazosin affinity might additionally be involved. Studies with the NPY analogues PYY, [Leu31, Pro34] NPY and NPY18-36 demonstrated that NPY acted via a Y1 NPY receptor. In addition to its direct vasoconstricting effects NPY also lowered the noradrenaline EC50 but did not appreciably affect maximal noradrenaline responses indicating possible potentiation. The potentiating NPY response occurred with similar agonist potency as the direct contractile NPY effects and also via a Y1 NPY receptor. The Ca2+ entry blocker nitrendipine (300 nM) reduced direct contractile responses to noradrenaline and NPY but did not affect the potentiation response to NPY.

Citing Articles

Effects of Nifedipine on Renal and Cardiovascular Responses to Neuropeptide Y in Anesthetized Rats.

Bischoff A, Stickan-Verfurth M, Michel M Molecules. 2021; 26(15).

PMID: 34361613 PMC: 8347858. DOI: 10.3390/molecules26154460.


Cardiac and Vascular α-Adrenoceptors in Congestive Heart Failure: A Systematic Review.

Kayki-Mutlu G, Papazisi O, Palmen M, Danser A, Michel M, Arioglu-Inan E Cells. 2020; 9(11).

PMID: 33158106 PMC: 7694190. DOI: 10.3390/cells9112412.


Effects of neuropeptide Y on the microvasculature of human skeletal muscle.

Mirman B, Ikeda I, Zhang Z, Liu Y, Yu L, Ehsan A Surgery. 2020; 168(1):155-159.

PMID: 32493616 PMC: 7325857. DOI: 10.1016/j.surg.2020.04.020.


DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.

Zhang J, Chen Q, Zhong J, Liu C, Zheng B, Gong Q Front Immunol. 2019; 10:1050.

PMID: 31134095 PMC: 6526751. DOI: 10.3389/fimmu.2019.01050.


Are blood vessels a target to treat lower urinary tract dysfunction?.

Michel M, Chess-Williams R, Hegde S Naunyn Schmiedebergs Arch Pharmacol. 2015; 388(7):687-94.

PMID: 26026700 DOI: 10.1007/s00210-015-1137-y.


References
1.
Michel M, Hanft G, Gross G . Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol. 1994; 111(2):539-46. PMC: 1909968. DOI: 10.1111/j.1476-5381.1994.tb14771.x. View

2.
Small D, Bolzon B, Cheung D . Endothelium-independent potentiating effects of neuropeptide Y in the rat tail artery. Eur J Pharmacol. 1992; 210(2):131-6. DOI: 10.1016/0014-2999(92)90663-o. View

3.
Michel M, Kenny B, Schwinn D . Classification of alpha 1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 1995; 352(1):1-10. DOI: 10.1007/BF00169183. View

4.
Michel M . Receptors for neuropeptide Y: multiple subtypes and multiple second messengers. Trends Pharmacol Sci. 1991; 12(10):389-94. DOI: 10.1016/0165-6147(91)90610-5. View

5.
Minneman K . Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+. Pharmacol Rev. 1988; 40(2):87-119. View